Emma C Tallantyre, Ruth Dobson, Joseph L J Froud, Frederika A St John, Valerie M Anderson, Tarunya Arun, Lauren Buckley, Nikos Evangelou, Helen L Ford, Ian Galea, Sumi George, Orla M Gray, Aimee M Hibbert, Mo Hu, Stella E Hughes, Gillian Ingram, Seema Kalra, Chia-Hui E Lim, Joela T M Mathews, Gavin V McDonnell, Naomi Mescall, Sam Norris, Stephen J Ramsay, Claire M Rice, Melanie J Russell, Marianne J Shawe-Taylor, Thomas E Williams, Katharine E Harding, Neil P Robertson
BACKGROUND AND PURPOSE: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation. METHODS: Treatment data on 4366 consecutive people with relapse-onset multiple sclerosis (MS) were pooled from 13 UK specialist centres during 2021...
April 3, 2024: European Journal of Neurology